📄 Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein

© 2015, American Society for Microbiology. Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. Wetested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8+ T cells and virusneutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.

keywords 🔗 syndrome coronavirus (1074) 🔗 neutralizing antibodies (122) 🔗 dipeptidyl peptidase (47) 🔗 respiratory syndrome (2004)

download 🔖 [BibTeX]